Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Last year, Pharma Intelligence launched the Clinical and Research Excellence (CARE) Awards to recognize and honor the vital contributions of those making a difference within clinical R&D. The inaugural event was a huge success and we were extremely proud that it enabled our industry to recognize its stars. As such, we are pleased to announce that the 2017 CARE Awards are now open for nominations.
In light of the ever evolving R&D landscape, we are introducing new categories to highlight notable achievements around rare disease drug development, patient centricity in trials as well as outcomes research. The awards will continue to showcase other key accomplishments, including excellence in trial conduct and design, technological advancements, and collaborative efforts between individuals, departments, or companies through the following categories:
Next year’s CARE Awards ceremony will take place at the State Room in Boston, MA on April 5th, 2017, during which we’ll celebrate the success, innovation, and dedication of the teams and individuals committed to bringing new drugs to market to fulfill today’s most significant unmet medical needs.
There’s no limit to the number of nominations you can enter, but the deadline for entries is January 20th, 2017. For more information on the CARE awards, including the category details and how to enter, visit the 2017 website at https://ibiawards.com/careawards/.
Scrip: industry news and insights
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Topics Clinical Trials Deal trends
Citeline
Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.
Topics Cancer Clinical Trials Research
Pink Sheet: global policy and regulatory coverage
AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.
Topics Cancer Clinical Trials
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
To build and maintain gold-standard, next generation R&D intelligence tools, Sitetrove, Trialtrove, Pharmaprojects, and Trialpredict have been undergoing a major program of investment. In addition to the many new and exciting changes on the horizon, the robust and reliable Citeline tools that you use to inform your business decisions will formally join Informa’s Pharma Intelligence family of brands.
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
